Regulus Therapeutics Inc. (NASDAQ:RGLS)‘s stock had its “ourperform” rating reaffirmed by analysts at Wedbush in a research report issued on Monday. They presently have a $4.00 target price on the biopharmaceutical company’s stock. Wedbush’s price objective suggests a potential upside of 320.34% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Chardan Capital reduced their price target on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, June 13th. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research report on Wednesday, July 12th. BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the company a “hold” rating in a research report on Monday, June 12th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Finally, ValuEngine downgraded shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company’s stock. Regulus Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.58.

Shares of Regulus Therapeutics (NASDAQ RGLS) opened at 0.9516 on Monday. The company’s market cap is $50.61 million. Regulus Therapeutics has a 12 month low of $0.86 and a 12 month high of $3.81. The stock has a 50 day moving average of $1.00 and a 200-day moving average of $1.34.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.10. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. On average, analysts forecast that Regulus Therapeutics will post ($1.10) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock Rating Reaffirmed by Wedbush” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/08/09/regulus-therapeutics-inc-nasdaqrgls-stock-rating-reaffirmed-by-wedbush.html.

In related news, CFO Daniel R. Chevallard acquired 54,945 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were acquired at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the purchase, the chief financial officer now owns 59,415 shares in the company, valued at $54,067.65. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William H. Rastetter acquired 274,725 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were bought at an average price of $0.91 per share, for a total transaction of $249,999.75. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 549,450 shares of company stock worth $500,000. Company insiders own 4.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of RGLS. Teachers Advisors LLC boosted its position in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 9,804 shares during the period. Wells Fargo & Company MN boosted its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the last quarter. Wedbush Securities Inc. boosted its stake in Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 93,420 shares during the last quarter. South Dakota Investment Council boosted its stake in Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 186,130 shares during the last quarter. Finally, Tudor Investment Corp ET AL boosted its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares during the last quarter. Institutional investors and hedge funds own 21.09% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.